Prof. Robert Ritzel, Division of Endocrinology, Munich and University of Heidelberg, Germany, presents effective treatment simplification for people with T2D using fixed ration combination of iGlarLixi.

This video explains WEQAYA's strategy on Nirsevimab Implementation

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

This evidence-based 3.17-minute video explores how uncontrolled atopic dermatitis creates cumulative disease burden beyond visible skin manifestations. Discover the hidden burden—psychological, social, and systemic impacts often overlooked—and the long-term implications of chronic inflammation. Learn to recognize progression patterns and the critical importance of early intervention strategies.